Selected Grants
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment, for Common EGFR-Mutated
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2025 - 2030Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Clinical TrialPrincipal Investigator · Awarded by OncoC4 · 2025 - 2029Investigating the impact of intratumoral PCSK9 on antigen presentation in NSCLC
ResearchPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2025 - 2026Phase Ib Study of MEM-288 Oncolytic Virus in Combination with Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
ResearchPrincipal Investigator · Awarded by Bristol-Myers Squibb Foundation · 2023 - 2026External Relationships
- Dava Oncology
- Johnson & Johnson
- Roche/Genentech
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.